TGA lets Lifeblood produce first faecal transplants for use outside of clinical trials
Faecal microbiota transplant will now be available to patients outside clinical trials.
Red Cross Lifeblood has received Australia’s first approval to produce faecal microbiota transplants for treating Clostridioides difficile outside of a clinical trial.
Hospitals can now order supplies of Lifeblood-processed faecal microbiota transplants (FMT) to administer to patients with C. difficile who do not respond to antibiotics.
